Baseline Plasma Gas6 Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients

Table 2

Comparison of plasma Gas6, sAxl, and sMerTK concentrations at different time points (t0, t7, and t14) between patients with an adverse disease evolution (deceased or transferred to ICU) vs. all other patients. Values are expressed as median (IQR). Bold text highlights the statistically significant results.

Laboratory findings (ng/ml)	Adverse disease evolution ()	All other patients ()		value
Gas6
t0	58.3 (43.8-75.2)	46.0 (37.3-57.9)	-2.548	0.011
t7	40.5 (36.9-45.5)	34.6 (26.9-47.0)	-1.552	0.121
t14	38.3 (28.6-86.2)	36.1 (28.1-41.4)	-0.580	0.562
sAxl
t0	18.8 (9.5-26.7)	16.0 (10.7-27.8)	-0.057	0.954
t7	33.3 (14.7-49.2)	25.8 (15.1-39.4)	-0.496	0.620
t14	20.3 (17.8-32.3)	23.1 (14.8-29.8)	-0.433	0.665
sMerTK
t0	36.9 (21.8-39.6)	33.2 (26.5-38.2)	-1.148	0.251
t7	31.5 (21.9-33.7)	26.9 (21.4-35.2)	-0.939	0.348
t14	21.2 (20.9-21.3)	25.3 (21.9-34.2)	1.530	0.126